BioSig to Present at NobleCon18 Capital Markets Conference
April 07 2022 - 8:30AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that Kenneth L. Londoner, Chairman and
CEO of BioSig Technologies, will be presenting at NobleCon18 -
Noble Capital Markets’ Eighteenth Annual Investor Conference at the
Hard Rock Hotel & Casino, Hollywood, Florida on Wednesday,
April 20, 2022 at 9:30 AM ET. Conference attendees will also have
the opportuntity to meet BioSig management during breakout sessions
scheduled for 1:00 PM ET on Wednesday April 20, 2022.
A high-definition, video webcast of the presentation
will be available the following day via this
link.
A replay of the presentation will be available the following day
on the BioSig Website. The presentation will be part of a complete
catalog of presentation available at Noble Capital Market’s
Conference website and on Channelcheck [www.channelcheck.com] the
investor portal created by Noble. The webcast will be archived for
90 days following the event.
The PURE EP™ System is an FDA 510(k) cleared non-invasive class
II device that aims to enhance physician workflow and increase
procedural efficiency and efficacy in cardiac electrophysiology. To
date, 75 physicians have completed more than
2,200 patient cases with the PURE EP™ System.
Clinical data acquired by the PURE EP™ System in a multi-center
study at Texas Cardiac Arrhythmia Institute at St. David's Medical
Center, Mayo Clinic Jacksonville, and Massachusetts General
Hospital was recently published in the Journal of Cardiovascular
Electrophysiology and is available electronically with open access
via the Wiley Online Library. Study results showed 93%
consensus across the blinded reviewers with a 75% overall
improvement in intracardiac signal quality and confidence in
interpreting PURE EP™ signals over conventional sources.
About Noble Capital Markets, Inc.Noble Capital
Markets (“Noble”) is a research driven investment bank that has
supported small & microcap companies since 1984. As a FINRA and
SEC licensed broker dealer Noble provides institutional-quality
equity research, merchant and investment banking, and order
execution services. In 2005, Noble established NobleCon, an
investor conference that has grown substantially over the last
decade. Noble launched www.channelchek.com in 2018 - an
investor community dedicated exclusively to public small and
micro-cap companies and their industries. Channelchek is the first
service to offer institutional-quality research to the public, for
FREE at every level without a subscription. More than 6,000 public
emerging growth companies are listed on the site, with growing
content including research, webcasts, podcasts, and balanced
news.
About BioSig TechnologiesBioSig
Technologies is a medical technology company commercializing a
proprietary biomedical signal processing platform designed
to improve signal fidelity and uncover the full range of ECG
and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EPä System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
203 409-5444, x 133
aballou@biosigtech.com
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024